Sinopharm to Sell Covid-19 Vaccine by Year-End, Announces Cost
▲Click above to subscribe 点击上方蓝字关注我们▲
(Yicai Global) Aug. 18 -- China National Pharmaceutical Group is expecting to bring its first inactivated Covid-19 vaccine onto the market by the end of this year with an attractive price point.
The jab, developed by Sinopharm's unit the Beijing Institute of Biological Products, began phase-three clinical trials in the United Arab Emirates in June, Guangming Daily reported, citing the Beijing-based firm's Chairman Liu Jingzhen.
The chief was sold on the safety of the new product. "I got two doses and have no adverse reactions."
Moreover, price should not be an issue. Two doses of 4 micrograms each should cost less than CNY1,000 (USD144), said Liu. The first dose should be 97 percent effective in about two weeks and after the second shot, the efficacy rate should reach 100 percent, according to the chairman.
Sinopharm has put its eggs in many baskets as it is pursuing two inactivated vaccines, as well as one genetically modified one against the virus that is ravaging the world. The parent company has invested about CNY2 billion (USD288.5 million) to build production capacity, said Liu.
In the beginning, the Beijing unit's output should reach 120 million inactivated vaccine doses a year. That facility has already been given the green light by regulators. Moreover, another subsidiary, the Wuhan Institute of Biological Products, could make 100 million doses of an inoculation that has already passed phase-two clinical trials.
The third genetically modified vaccine, developed by the National Vaccine & Serum Institute, is expected to start clinical trials in October and if successful, it could be mass-produced fast, said Liu.
However, not everyone in China may need to get protected against the virus, according to the unlisted firm's chief. "It is not necessary for each and every one of China’s population of 1.4 billion people to get vaccinated. It is necessary for students and people who work in densely populated cities but not for those who live in sparsely populated rural areas."
Editor: Emmi Laine
Source: Yicai Global
Another vaccine developed by CanSino Biologics Inc. was issued a patent this month 11 for its Covid-19 vaccine candidate Ad5-nCOV, making it the first Covid-19 vaccine to be granted a patent in China, or perhaps the whole world. More great news coming~
People are selling "vaccine" online for 498 RMB 新冠疫苗498元一支朋友圈开卖？
China allows the return of people from 36 and more countries
Contributions will be appreciated！
欢迎投稿！
▲ QQ group
▲ Official account